CHARLES RIVER LABORATORIES (CRL) Stock News
NYSE:CRL - New York Stock Exchange, Inc. - US1598641074 - Common Stock - Currency: USD
CRL Latest News, Press Relases and Analysis
Charles River Laboratories Announces First-Quarter 2025 Results
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect
Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results tomorrow before the bell. Here’s what to expect.
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: PGNY
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year?
ON Semiconductor Corporation (ON): Among the Worst Performing Stocks in S&P 500 So Far in 2025
We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a look at where ON Semiconductor Corporation (NASDAQ:ON) stands against other worst performing stocks this year. After a two-year surge of 53%, marking the best performance for the broad market index […]
Charles River Laboratories International, Inc. (CRL): Among the Worst Performing Stocks in S&P 500 So Far in 2025
We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a look at where Charles River Laboratories International, Inc. (NYSE:CRL) stands against other worst performing stocks this year. After a two-year surge of 53%, marking the best performance for the broad […]
Teradyne, Inc. (TER): Among the Worst Performing Stocks in S&P 500 So Far in 2025
We recently published a list of the 11 Worst Performing Stocks in S&P 500 So Far in 2025. In this article, we will take a look at where Teradyne, Inc. (NASDAQ:TER) stands against other worst performing stocks this year. After a two-year surge of 53%, marking the best performance for the broad market index since […]
Nasdaq Seeks SEC Nod to List 21Shares Dogecoin ETF
- Nasdaq's filing would add the popular memecoin to growing crypto ETF lineup. - SEC continues to push back decisions on multiple crypto fund applications. - Analysts project final rulings on altcoin ETFs by October 2025 deadline.
2 Millionaire-Maker Electric Vehicle (EV) Stocks
Last year, Lucid only had one EV on the market: The Lucid Air. The Air was an impressive initial vehicle for Lucid, helping grow the company's sales to nearly $1 billion. Analysts expect sales to grow by 82% this year, and another 91% next year, due to demand for Lucid's SUV platform.
Is Micron Technology, Inc. (MU) the Cheap Semiconductor Stock to Buy Now?
We recently published a list of 10 Cheap Semiconductor Stocks to Buy Now. In this article, we are going to take a look at where Micron Technology, Inc. (NASDAQ:MU) stands against other cheap semiconductor stocks to buy now. The semiconductor industry has been experiencing a recent wave of surging demand, technological innovation, and shifting macroeconomic […]
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: PINC
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
Here's How Charles River is Placed Just Ahead of Q1 Earnings
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
Upslope Capital Management Sold Charles River (CRL) Due to Thesis Break
Upslope Capital Management, an investment management firm, released its first-quarter 2025 investor letter. A copy of the letter can be downloaded here. The First quarter was challenging for the fund. However, the world has transformed in the two weeks since March 31, due to a drastic realignment of international trade rules. As a result, markets […]
Mentions: TSLA
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
Is HF Foods Group Inc. (HFFG) the Best Rising Penny Stock to Buy According to Analysts?
We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where HF Foods Group Inc. (NASDAQ:HFFG) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
We recently published a list of 20 Mid-Cap Stocks Insiders Were Buying in Q1 2025. In this article, we are going to take a look at where Charles River Laboratories International, Inc. (NYSE:CRL) stands against other mid-cap stocks insiders were buying in Q1 2025. Stock markets tumbled on Wednesday, with technology shares leading the slide […]
Jim Cramer Approves of Rubrik (RBRK): “Get Hit with Ransomware? You Call Rubrik — That’s Why You Own It!”
We recently published a list of Jim Cramer’s List of 16 Stocks to Buy Right Now. In this article, we are going to take a look at where Rubrik, Inc. (NYSE:RBRK) stands against other stocks on Jim Cramer’s list to buy right now. On Monday, April 14th, Jim Cramer opened the Mad Money episode with a striking […]
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
Amid market turbulence and policy shifts, do two of the S&P 500’s steepest decliners, DECK and CRL, offer deep value or signal deeper trouble ahead?
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened
JPMorgan, which holds a ‘Neutral’ rating on the stock, opined that Charles River could see disruption from customers reassessing its preclinical strategies in the near term.